Clinical Outcomes and Inflammatory Responses in Viral vs. Bacterial Sepsis

Launched by SICHUAN PROVINCIAL PEOPLE'S HOSPITAL · Jul 8, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the differences in outcomes and inflammatory responses between patients with viral sepsis, particularly those with COVID-19, and those with bacterial sepsis. The researchers at Sichuan Provincial People's Hospital are looking to understand how these two types of sepsis affect patients in the Intensive Care Unit (ICU) by reviewing data from patients admitted between July 2021 and December 2023. The main goal is to find reliable markers that can help doctors diagnose and treat these conditions more effectively, leading to better care for patients.

To be part of this study, patients must be 18 years or older and have been diagnosed with sepsis according to specific criteria. They should either have bacterial sepsis confirmed by positive cultures or viral sepsis linked to COVID-19 confirmed by a special test. However, patients with mixed infections, those who haven't met the sepsis criteria, or those who received certain experimental treatments will not be included. Participants can expect their health information to be analyzed to help improve future treatments for sepsis. This trial is currently recruiting patients, and all genders are welcome to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients diagnosed with sepsis according to Sepsis 3.0 criteria.
• • 2. Patients with confirmed bacterial sepsis based on positive bacterial cultures.
• • 3. Patients with confirmed viral sepsis, specifically COVID-19, diagnosed via RT-PCR for SARS-CoV-2 for viral group and negative for bacterial group.
• • 4. Patients aged 18 years and older.
• • 5. Patients admitted to the ICU during the study period.
• Exclusion Criteria:
• • 1. Patients with mixed bacterial and viral infections.
• • 2. Patients with sepsis not meeting the Sepsis 3.0 criteria.
• • 3. Patients who received immunomodulatory therapies other than standard treatments (e.g., investigational drugs).
• • 4. Pregnant or breastfeeding women.